Overview

AHSCT Combined With CAR-T Cells in the Treatment of Refractory and Relapsed Multiple Myeloma

Status:
Recruiting
Trial end date:
2025-03-01
Target enrollment:
Participant gender:
Summary
Clinical Study on the Safety and Effectiveness of Autologous Hematopoietic Stem Cell Transplantation Combined With CAR-T Cells in the Treatment of Refractory and Relapsed Multiple Myeloma
Phase:
Phase 1
Details
Lead Sponsor:
Zhejiang University
Collaborator:
Yake Biotechnology Ltd.